Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05784350
Other study ID # 0068-23-MMC
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 1, 2024
Est. completion date May 1, 2028

Study information

Verified date March 2024
Source Meir Medical Center
Contact Sara Dichtwald, Dr
Phone 972-9-7472133
Email sara.dichtwald@clalit.org.il
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hypotension is a common side-effect of general anesthesia induction and is related to adverse outcomes including significantly increasing risk of one-year mortality. Even short durations of intraoperative hypotension have been associated with acute kidney injury (AKI) and myocardial injury.Half of all the patients were fluid-responsive, pointing to volume status as a significant risk factor. Ultrasound measurements of inferior vena cava (IVC) diameter with respiration, including the maximal diameter of the IVC (dIVCmax) at the end of expiration during spontaneous respiration and the collapsibility index (CI), have been recommended as rapid and noninvasive methods for estimating volume status. In attempt to prevent hypotension after spinal anesthesia induction, Ondansetron, a serotonin receptor antagonist, has been used effectively . Research Question Can preoperative IVC-US guided fluid optimization and intravenous ondansetron reduce the incidence of general anesthesia-induced hypotension in adult patients undergoing elective non-cardiac non-obstetric surgery?


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date May 1, 2028
Est. primary completion date May 1, 2028
Accepts healthy volunteers No
Gender All
Age group 19 Years to 99 Years
Eligibility Inclusion Criteria: 1. Age > 18 2. Elective, non-cardiac, non-obstetric surgery under general anesthesia 3. American Society of Anesthesiologists physical status classification I - III Exclusion Criteria: 1. MAP below 60 mmhg prior to the induction of general anesthesia. 2. Patients treated with angiotensin converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) on the day of surgery. 3. Patients with heart failure with ejection fraction (EF) < 40%. 4. Patients with documented acute or chronic renal failure. 5. Patients with hepatic failure. 6. Patients with neuraxial (spinal/epidural) anesthesia performed before induction of general anesthesia. 7. Patients with suspected difficult airway. 8. Patients with documented allergy to Ondansetron or prolonged QT-syndrome. -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone
group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L. Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia.

Locations

Country Name City State
Israel Meir Medical Center Kfar Saba

Sponsors (1)

Lead Sponsor Collaborator
Meir Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of preoperative IVC-guided fluid optimization and intravenous ondansetron in reducing the incidence of hypotension after the induction of general anesthesia To determine the efficacy of preoperative IVC-guided fluid optimization and intravenous ondansetron in reducing the incidence of hypotension after the induction of general anesthesia in adults presenting for elective non-cardiac, non-obstetric surgery. 5 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT01451294 - Effect of Blood Pressure on rSO2 in Carotid Endarterectomy (CEA) N/A